{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:50:12Z","timestamp":1791921012973,"version":"4.3.4"},"reference-count":293,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771870 and 81603142"],"award-info":[{"award-number":["81771870 and 81603142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer remains a major cause of death globally. Given its relapsing and fatal features, curing cancer seems to be something hardly possible for the majority of patients. In view of the development in cancer therapies, this article summarizes currently available cancer therapeutics and cure potential by cancer type and stage at diagnosis, based on literature and database reviews. Currently common cancer therapeutics include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, treatment with curative intent by these methods are mainly eligible for patients with localized disease or treatment-sensitive cancers and therefore their contributions to cancer curability are relatively limited. The prognosis for cancer patients varies among different cancer types with a five-year relative survival rate (RSR) of more than 80% in thyroid cancer, melanoma, breast cancer, and Hodgkin\u2019s lymphoma. The most dismal prognosis is observed in patients with small-cell lung cancer, pancreatic cancer, hepatocellular carcinoma, oesophagal cancer, acute myeloid leukemia, non-small cell lung cancer, and gastric cancer with a five-year RSR ranging between 7% and 28%. The current review is intended to provide a general view about how much we have achieved in curing cancer as regards to different therapies and cancer types. Finally, we propose a small molecule dual-targeting broad-spectrum anticancer strategy called OncoCiDia, in combination with emerging highly sensitive liquid biopsy, with theoretical curative potential for the management of solid malignancies, especially at the micro-cancer stage.<\/jats:p>","DOI":"10.3390\/cancers11111782","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T09:11:27Z","timestamp":1573636287000},"page":"1782","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-2760","authenticated-orcid":false,"given":"Shuncong","family":"Wang","sequence":"first","affiliation":[{"name":"KU Leuven, Campus Gasthuisberg, Faculty of Medicine, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-0132","authenticated-orcid":false,"given":"Yewei","family":"Liu","sequence":"additional","affiliation":[{"name":"KU Leuven, Campus Gasthuisberg, Faculty of Medicine, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Feng","sequence":"additional","affiliation":[{"name":"KU Leuven, Campus Gasthuisberg, Faculty of Medicine, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7720-5077","authenticated-orcid":false,"given":"Johan","family":"Swinnen","sequence":"additional","affiliation":[{"name":"KU Leuven, Campus Gasthuisberg, Faculty of Medicine, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-7565","authenticated-orcid":false,"given":"Yicheng","family":"Ni","sequence":"additional","affiliation":[{"name":"KU Leuven, Campus Gasthuisberg, Faculty of Medicine, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","first-page":"290","article-title":"The White House Launches a Cancer Moonshot: Despite Funding Questions, the Progress Appears Promising","volume":"41","author":"Barlas","year":"2016","journal-title":"Pharm. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428194.2017.1335398","article-title":"Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades","volume":"59","author":"Sun","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.2147\/CMAR.S173099","article-title":"The fluctuating incidence, improved survival of patients with breast cancer, and disparities by age, race, and socioeconomic status by decade, 1981-2010","volume":"10","author":"Lu","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"59820","DOI":"10.18632\/oncotarget.10930","article-title":"Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.7150\/jca.17349","article-title":"Survival changes in Patients with Synovial Sarcoma, 1983-2012","volume":"8","author":"Wang","year":"2017","journal-title":"J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cdd.2008.150","article-title":"Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009","volume":"16","author":"Kroemer","year":"2009","journal-title":"Cell Death Differ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s004419900160","article-title":"Apoptosis and cancer chemotherapy","volume":"301","author":"Makin","year":"2000","journal-title":"Cell Tissue Res."},{"key":"ref_13","first-page":"277","article-title":"Apoptosis in radiation therapy: A double-edged sword","volume":"34","year":"2012","journal-title":"Exp. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.11.002","article-title":"Mitotic catastrophe and cancer drug resistance: A link that must to be broken","volume":"24","author":"Denisenko","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/CAD.0000000000000497","article-title":"The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: The potential impact of immunotherapy","volume":"28","author":"Zagar","year":"2017","journal-title":"Anti Cancer Drugs"},{"key":"ref_16","first-page":"5","article-title":"Assessing the percent of necrosis after neoadjuvant chemotherapy with 24hr infusional cisplatin\/3 days Doxorubicin intermittent with Ifosfamide-Doxorubicin for osteosarcoma","volume":"8","author":"Samimi","year":"2014","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6","article-title":"Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor","volume":"56","author":"Picci","year":"1985","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1007\/s00330-017-5198-9","article-title":"Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation","volume":"28","author":"Varzaneh","year":"2018","journal-title":"Eur. Radiol."},{"key":"ref_19","first-page":"836","article-title":"The clinical classification of malignant tumours: The TNM system","volume":"105","author":"Sellers","year":"1971","journal-title":"Can. Med. Assoc. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.3748\/wjg.v18.i39.5521","article-title":"Treatment of locally advanced rectal cancer: Controversies and questions","volume":"18","author":"Trakarnsanga","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2016.69.9678","article-title":"Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer","volume":"35","author":"Rosenzweig","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2014.60.1054","article-title":"Advances and challenges in treatment of locally advanced rectal cancer","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/archinte.1972.03650050108025","article-title":"Cell kill hypothesis","volume":"130","author":"Kurnick","year":"1972","journal-title":"Arch. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JOP.2012.000806","article-title":"Use of the word \u201dcure\u201d in oncology","volume":"9","author":"Miller","year":"2013","journal-title":"J. Oncol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.lpm.2017.09.025","article-title":"Known, new and emerging risk factors of hepatocellular carcinoma (review)","volume":"46","author":"Trad","year":"2017","journal-title":"Presse Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jnci\/djt270","article-title":"Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: A meta-analysis","volume":"105","author":"Oba","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: An overview of measures, uses, and interpretation","volume":"2014","author":"Mariotto","year":"2014","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/1097-0142(19951115)76:10<1687::AID-CNCR2820761002>3.0.CO;2-I","article-title":"The relative survival rate","volume":"76","author":"Henson","year":"1995","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1002\/cam4.1706","article-title":"A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations","volume":"7","author":"Makkar","year":"2018","journal-title":"Cancer Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cgh.2006.03.007","article-title":"Promoter methylation and response to chemotherapy and radiation in esophageal cancer","volume":"4","author":"Hamilton","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(15)00223-5","article-title":"Global cancer surgery: Delivering safe, affordable, and timely cancer surgery","volume":"16","author":"Sullivan","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/SLA.0b013e3182583e2e","article-title":"Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: Evidence from randomized and nonrandomized clinical trials","volume":"256","author":"Zeng","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/jso.23438","article-title":"Laparoscopic gastrectomy for advanced gastric cancer: Are the long-term results comparable with conventional open gastrectomy? A systematic review and meta-analysis","volume":"108","author":"Choi","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","article-title":"Gastric cancer","volume":"388","author":"Sagaert","year":"2016","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1804923","article-title":"Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer","volume":"379","author":"Melamed","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2468-1253(19)30006-8","article-title":"Laparoscopic pancreatoduodenectomy: Safety concerns and no benefits","volume":"4","author":"Strobel","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2468-1253(19)30004-4","article-title":"Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): A multicentre, patient-blinded, randomised controlled phase 2\/3 trial","volume":"4","author":"Bosscha","year":"2019","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMoa1806395","article-title":"Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer","volume":"379","author":"Ramirez","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cgh.2016.08.041","article-title":"Long-term Recurrence-free Survival After Standard Endoscopic Resection Versus Surgical Resection of Submucosal Invasive Colorectal Cancer: A Population-based Study","volume":"15","author":"Belderbos","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1007\/s00464-014-3618-3","article-title":"Endoscopic resection as the first-line treatment for early colorectal cancer: Comparison with surgery","volume":"28","author":"Heo","year":"2014","journal-title":"Surg. Endosc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ajg.2015.427","article-title":"Long-Term Outcome of Endoscopic Resection vs. Surgery for Early Gastric Cancer: A Non-inferiority-Matched Cohort Study","volume":"111","author":"Pyo","year":"2016","journal-title":"Am.J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1572-0241.2008.01889.x","article-title":"A comparison of endoscopic treatment and surgery in early esophageal cancer: An analysis of surveillance epidemiology and end results data","volume":"103","author":"Das","year":"2008","journal-title":"Am.J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/jama.2019.3736","article-title":"Is It Time for Safeguards in the Adoption of Robotic Surgery","volume":"321","author":"Sheetz","year":"2019","journal-title":"JAMA"},{"key":"ref_52","unstructured":"Administration, U.F.a.D (2019, November 07). Caution When Using Robotically-Assisted Surgical Devices in Women\u2019s Health Including Mastectomy and Other Cancer-Related Surgeries: FDA Safety Communication, Available online: https:\/\/www.fda.gov\/medicaldevices\/safety\/alertsandnotices\/ucm632142.htm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamasurg.2016.4753","article-title":"Defining a Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy in the United States","volume":"152","author":"Adam","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2010.04.024","article-title":"The learning curve of robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium","volume":"58","author":"Hayn","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.eururo.2012.08.059","article-title":"Costs of radical prostatectomy for prostate cancer: A systematic review","volume":"65","author":"Bolenz","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00383-008-2240-7","article-title":"Case selection in minimally invasive surgical treatment of neuroblastoma","volume":"24","author":"Boutros","year":"2008","journal-title":"Pediatr. Surg. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1046\/j.1365-2168.2002.02168.x","article-title":"Complications of radiofrequency coagulation of liver tumours","volume":"89","author":"Mulier","year":"2002","journal-title":"Br. J. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ctrv.2013.03.007","article-title":"Review of current thermal ablation treatment for lung cancer and the potential of electrochemotherapy as a means for treatment of lung tumours","volume":"39","author":"Jahangeer","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00261-004-0253-9","article-title":"A review of the general aspects of radiofrequency ablation","volume":"30","author":"Ni","year":"2005","journal-title":"Abdom. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.29486","article-title":"Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis","volume":"67","author":"Finn","year":"2018","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: Modalities, indication, and patient selection","volume":"62","author":"Sieghart","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"62742","DOI":"10.18632\/oncotarget.18409","article-title":"Improving radiotherapy in cancer treatment: Promises and challenges","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0377-1237(10)80132-7","article-title":"Radiotherapy: Basic Concepts and Recent Advances","volume":"66","author":"Mehta","year":"2010","journal-title":"Med. J. Armed Forces India"},{"key":"ref_65","unstructured":"Reference, M.D. (2019, November 07). Definition for Heavy Ion. Available online: http:\/\/www.reference.md\/files\/D020\/mD020450.html."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02841860701218626","article-title":"A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors","volume":"46","author":"Palm","year":"2007","journal-title":"Acta Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1038\/s41598-019-46630-w","article-title":"Focused very high-energy electron beams as a novel radiotherapy modality for producing high-dose volumetric elements","volume":"9","author":"Kokurewicz","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2016.10.001","article-title":"National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer","volume":"97","author":"Higgins","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.14338\/IJPT-15-00013","article-title":"Particle Therapy Statistics in 2014","volume":"2","author":"Jermann","year":"2015","journal-title":"Int. J. Part. Ther."},{"key":"ref_70","unstructured":"Group, P.T.C.-O (2019, November 07). Particle Therapy Patient Statistics (per End of 2016). Available online: https:\/\/www.ptcog.ch\/archive\/patient_statistics\/Patientstatistics-updateDec2016.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","article-title":"Proton therapy-Present and future","volume":"109","author":"Mohan","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijrobp.2017.10.015","article-title":"Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial","volume":"100","author":"Thomas","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijrobp.2016.07.022","article-title":"Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials","volume":"96","author":"Ramroth","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijrobp.2003.10.044","article-title":"Impact of FDG-PET on radiation therapy volume delineation in non\u2013small-cell lung cancer","volume":"59","author":"Bradley","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ijrobp.2018.04.016","article-title":"Review of Real-Time 3-Dimensional Image Guided Radiation Therapy on Standard-Equipped Cancer Radiation Therapy Systems: Are We at the Tipping Point for the Era of Real-Time Radiation Therapy","volume":"102","author":"Keall","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1200\/JCO.18.02366","article-title":"Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation","volume":"37","author":"Jimenez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer","volume":"36","author":"Pan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved","volume":"88","author":"Brown","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ijrobp.2018.10.008","article-title":"Stereotactic Radiation for Ultra-Central Lung Tumors: Good Idea, or Ultra-Risky","volume":"103","author":"Palma","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Chicas-Sett, R., Morales-Orue, I., Castilla-Martinez, J., Zafra-Martin, J., Kannemann, A., Blanco, J., Lloret, M., and Lara, P.C. (2019). Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092173"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1088\/0031-9155\/49\/18\/N03","article-title":"The use of gold nanoparticles to enhance radiotherapy in mice","volume":"49","author":"Hainfeld","year":"2004","journal-title":"Phys. Med. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.addr.2015.12.012","article-title":"Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements","volume":"109","author":"Her","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1088\/0031-9155\/57\/24\/8309","article-title":"Enhanced proton treatment in mouse tumors through proton irradiated nanoradiator effects on metallic nanoparticles","volume":"57","author":"Kim","year":"2012","journal-title":"Phys. Med. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1134\/S1547477117030153","article-title":"Importance of electric fields from ionized nanoparticles for radiation therapy","volume":"14","author":"Shmatov","year":"2017","journal-title":"Phys. Part. Nucl. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1802228","DOI":"10.1002\/adma.201802228","article-title":"Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.1021\/acsnano.7b08225","article-title":"Oxygen-Self-Produced Nanoplatform for Relieving Hypoxia and Breaking Resistance to Sonodynamic Treatment of Pancreatic Cancer","volume":"11","author":"Chen","year":"2017","journal-title":"Acs Nano"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1078-0432.CCR-16-1297","article-title":"First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas","volume":"23","author":"Bonvalot","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"418","DOI":"10.7150\/thno.14018","article-title":"Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial","volume":"6","author":"Kotb","year":"2016","journal-title":"Theranostics"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"20180365","DOI":"10.1259\/bjr.20180365","article-title":"AGuIX\u00ae from bench to bedside\u2014Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine","volume":"92","author":"Lux","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"023591","DOI":"10.1136\/bmjopen-2018-023591","article-title":"Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol","volume":"9","author":"Verry","year":"2019","journal-title":"BMJ Open"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2\u20133, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jama.2011.1139","article-title":"Use of radioactive iodine for thyroid cancer","volume":"306","author":"Haymart","year":"2011","journal-title":"JAMA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1056\/NEJMe1304041","article-title":"Fighting Prostate Cancer with Radium-223\u2014Not Your Madame\u2019s Isotope","volume":"369","author":"Vapiwala","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3322\/caac.21578","article-title":"Brachytherapy: An overview for clinicians","volume":"69","author":"Chargari","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_99","unstructured":"Hoppe, R.T., Phillips, T.L., and Roach, M. (2010). 13-Modern Principles of Brachytherapy Physics: From 2-D to 3-D to Dynamic Planning and Delivery. Leibel and Phillips Textbook of Radiation Oncology, W.B. Saunders. [3rd ed.]."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.5-suppl_2-1","article-title":"Radiotherapy-associated anemia: The scope of the problem","volume":"5","author":"Harrison","year":"2000","journal-title":"Oncologist"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040622313510730","article-title":"Radiation-induced small bowel disease: Latest developments and clinical guidance","volume":"5","author":"Stacey","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0974-7753.77528","article-title":"Radiation-induced Alopecia","volume":"2","author":"Ali","year":"2010","journal-title":"Int. J. Trichol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: A cohort study in the US SEER cancer registries","volume":"12","author":"Curtis","year":"2011","journal-title":"Lancet. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1200\/JCO.2017.72.6497","article-title":"Postoperative Pelvic Radiotherapy in Patients With Endometrial Cancer May Increase the Risk for Secondary Pelvic Cancers: A Post Hoc Analysis of Results From the TME, PORTEC-1, and PORTEC-2 Trials","volume":"35","author":"Wissing","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: Systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2013.551","article-title":"Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma","volume":"110","author":"Horwich","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hon.2377","article-title":"Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors","volume":"35","author":"Alfo","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Teng, C.J., Hu, Y.W., Chen, S.C., Yeh, C.M., Chiang, H.L., Chen, T.J., and Liu, C.J. (2016). Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djv314"},{"key":"ref_109","first-page":"410","article-title":"Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer","volume":"76","author":"Molenaar","year":"2017","journal-title":"Surgery"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clon.2004.06.007","article-title":"The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies","volume":"16","author":"Morgan","year":"2004","journal-title":"Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Lawrie, T.A., Winter-Roach, B.A., Heus, P., and Kitchener, H.C. (2015). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst. Rev., 12.","DOI":"10.1002\/14651858.CD004706.pub5"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1200\/JCO.2003.12.095","article-title":"Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study--JCOG9204","volume":"21","author":"Ando","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1634\/theoncologist.2017-0600","article-title":"Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis","volume":"24","author":"Hu","year":"2019","journal-title":"Oncologist"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"232","DOI":"10.12688\/f1000research.6760.1","article-title":"Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates","volume":"4","author":"Ashdown","year":"2015","journal-title":"F1000Research"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1200\/JCO.18.00089","article-title":"Phase I\/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2","volume":"37","author":"Macarulla","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1470-2045(14)70105-6","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial","volume":"15","author":"Primrose","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.19.01007","article-title":"Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma","volume":"37","author":"Chera","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamasurg.2016.5050","article-title":"Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Colon Cancer","volume":"152","author":"Manjelievskaia","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdz055","article-title":"De-escalated therapy for HR+\/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: Results of the PerELISA neoadjuvant study","volume":"30","author":"Guarneri","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201101131","article-title":"Role of intratumoural heterogeneity in cancer drug resistance: Molecular and clinical perspectives","volume":"4","author":"Saunders","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.13-S1-5","article-title":"Systemic chemotherapy for advanced non-small cell lung cancer: Recent advances and future directions","volume":"13","author":"Ramalingam","year":"2008","journal-title":"Oncologist"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.12-6-631","article-title":"Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen","volume":"12","author":"Paik","year":"2007","journal-title":"Oncologist"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Turkington, R.C., Knight, L.A., Blayney, J.K., Secrier, M., Douglas, R., Parkes, E.E., Sutton, E.K., Stevenson, L., McManus, D., and Halliday, S. (2019). Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut.","DOI":"10.1136\/gutjnl-2018-317624"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0140-6736(15)60410-X","article-title":"Proteomic analysis to identify biomarkers in the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases","volume":"385","author":"Sutton","year":"2015","journal-title":"Lancet"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): A randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-Paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., and de la Mora Jimenez, E. (2019). Nivolumab plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1910231"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2013.54.7844","article-title":"Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy","volume":"32","author":"Wong","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_140","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2015.08.021","article-title":"The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts","volume":"369","author":"Strecker","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2015.65.8153","article-title":"Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"34","author":"Monk","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1200\/JCO.2011.35.0660","article-title":"Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer","volume":"29","author":"Lara","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2010.32.5944","article-title":"Phase I\/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer","volume":"29","author":"Rudin","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ejca.2015.08.012","article-title":"Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab","volume":"51","author":"Eroglu","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_156","first-page":"9","article-title":"Treating with Checkpoint Inhibitors-Figure $1 Million per Patient","volume":"8","author":"Andrews","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Bianco, A., Perrotta, F., Barra, G., Malapelle, U., Rocco, D., and De Palma, R. (2019). Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194931"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Pinato, D.J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C., Power, D., Hatcher, O., and Falconer, A. (2019). Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2019.2785"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_162","first-page":"65","article-title":"1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT","volume":"9","author":"Albano","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JHC.S96085","article-title":"Surgical resection of localized hepatocellular carcinoma: Patient selection and special consideration","volume":"4","author":"Ma","year":"2017","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bju.13200","article-title":"Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: A propensity score matching study","volume":"117","author":"Takagi","year":"2016","journal-title":"BJU Int."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/TCRM.S153359","article-title":"Surgical injury: Comparing open surgery and laparoscopy by markers of tissue damage","volume":"14","author":"Maca","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for Cancer: A Trigger for Metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.amjsurg.2012.08.015","article-title":"Robot-assisted laparoscopic liver resection for hepatocellular carcinoma: Short-term outcome","volume":"205","author":"Lai","year":"2013","journal-title":"Am. J. Surg."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1470-2045(18)30357-7","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study","volume":"19","author":"Coughlin","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_169","first-page":"281","article-title":"Endoscopic management of early gastric cancer: Endoscopic mucosal resection or endoscopic submucosal dissection: Data from a Japanese high-volume center and literature review","volume":"25","author":"Uedo","year":"2012","journal-title":"Ann. Gastroenterol."},{"key":"ref_170","first-page":"445","article-title":"Endoscopic Treatment of Early Cancer of the Colon","volume":"11","author":"Ribeiro","year":"2015","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ajg.2017.58","article-title":"Risk for Incomplete Resection after Macroscopic Radical Endoscopic Resection of T1 Colorectal Cancer: A Multicenter Cohort Study","volume":"112","author":"Backes","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1111\/j.1572-0241.2000.03356.x","article-title":"Endoscopic perforation of the colon: Lessons from a 10-year study","volume":"95","author":"Anderson","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"Chen","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7326\/M17-0585","article-title":"Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis","volume":"169","author":"Talenfeld","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejrad.2010.12.091","article-title":"Comparison between surgery and radiofrequency ablation for stage I non-small cell lung cancer","volume":"81","author":"Kim","year":"2012","journal-title":"Eur.J. Radiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.juro.2008.01.114","article-title":"Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma","volume":"179","author":"Yoon","year":"2008","journal-title":"J. Urol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.3892\/ol.2016.4436","article-title":"Biliary tract perforation following percutaneous endobiliary radiofrequency ablation: A report of two cases","volume":"11","author":"Zhou","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4254\/wjh.v6.i3.107","article-title":"Complications of radiofrequency ablation of hepatic tumors: Frequency and risk factors","volume":"6","author":"Fonseca","year":"2014","journal-title":"World J. Hepatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0033-1333648","article-title":"Chemoembolization of hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2013","journal-title":"Semin. Interv. Radiol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/PPO.0b013e3181a27018","article-title":"Role of chemotherapy in Hodgkin\u2019s lymphoma","volume":"15","author":"Seam","year":"2009","journal-title":"Cancer J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0970-1591.60451","article-title":"Update on management of seminoma","volume":"26","author":"Alexander","year":"2010","journal-title":"Indian J. Urol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/02841869409121767","article-title":"Secondary malignancies following cancer chemotherapy","volume":"33","author":"Boffetta","year":"1994","journal-title":"Acta Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/cncr.23336","article-title":"Thromboembolic events with lenalidomide-based therapy for multiple myeloma","volume":"112","author":"Menon","year":"2008","journal-title":"Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1172\/JCI24586","article-title":"Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling","volume":"115","author":"Vincent","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13014-016-0690-y","article-title":"Radiotherapy for Non-Hodgkin\u2019s lymphoma: Still standard practice and not an outdated treatment option","volume":"11","author":"Zimmermann","year":"2016","journal-title":"Radiat. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fonc.2016.00013","article-title":"A Review of Radiotherapy-Induced Late Effects Research after Advanced Technology Treatments","volume":"6","author":"Newhauser","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S1470-2045(18)30931-8","article-title":"Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: A propensity score-weighted, retrospective, cohort study","volume":"20","author":"Mohamad","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2586512","DOI":"10.1155\/2016\/2586512","article-title":"Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer","volume":"2016","author":"Florenzano","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2004.10.016","article-title":"Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"22","author":"Teunissen","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1590\/S1677-5538.IBJU.2015.0542","article-title":"Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: A retrospective analysis","volume":"42","author":"Logghe","year":"2016","journal-title":"Int. Braz. J. Urol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/1055-9965.EPI-09-0892","article-title":"Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer","volume":"19","author":"Gilbert","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.molonc.2014.05.004","article-title":"Drug resistance to targeted therapies: Deja vu all over again","volume":"8","author":"Groenendijk","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2014.58.2320","article-title":"Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011","volume":"33","author":"Shih","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/jrms.JRMS_182_17","article-title":"Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance","volume":"22","author":"Zarrin","year":"2017","journal-title":"J. Res. Med. Sci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4143\/crt.2008.40.1.33","article-title":"Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin)","volume":"40","author":"Choi","year":"2008","journal-title":"Cancer Res. Treat."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13696998.2019.1582059","article-title":"CAR T-cells: Costs, comparisons, and commentary","volume":"22","author":"Hay","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.1090","article-title":"Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","article-title":"Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission","volume":"13","author":"Brown","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/pbc.24559","article-title":"Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review","volume":"60","author":"Mateos","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701874","article-title":"Role of the intensive care unit in children undergoing bone marrow transplantation with life-threatening complications","volume":"24","author":"Moreno","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The Diagnosis and Treatment of Prostate Cancer: A Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4048\/jbc.2015.18.4.378","article-title":"Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study","volume":"18","author":"Marcheselli","year":"2015","journal-title":"J. Breast Cancer"},{"key":"ref_213","unstructured":"(2019, November 07). Surveillance, Epidemiology, and End Results (SEER) Program SEER Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2018 Sub (1975-2016) (Katrina\/Rita Population Adjustment) -Linked To County Attributes-Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Available online: www.seer.cancer.gov."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"57","DOI":"10.14694\/EdBook_AM.2015.35.57","article-title":"Early detection of cancer: Past, present, and future","volume":"35","author":"Schiffman","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.bjc.6602750","article-title":"Ten years of marketing approvals of anticancer drugs in Europe: Regulatory policy and guidance documents need to find a balance between different pressures","volume":"93","author":"Apolone","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2015.23","article-title":"Diagnosing cancer earlier: Reviewing the evidence for improving cancer survival","volume":"112","author":"Hiom","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1136\/bmj.i5792","article-title":"Cancer drugs, survival, and ethics","volume":"355","author":"Wise","year":"2016","journal-title":"BMJ"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4274\/2017.26.suppl.08","article-title":"Radioactive Iodine Therapy of Differentiated Thyroid Carcinoma: Redesigning the Paradigm","volume":"26","author":"Goldsmith","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"l5221","DOI":"10.1136\/bmj.l5221","article-title":"Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014\u20132016: Cross sectional analysis","volume":"366","author":"Naci","year":"2019","journal-title":"BMJ"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41571-019-0227-z","article-title":"The changing therapeutic landscape of head and neck cancer","volume":"16","author":"Cramer","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: Current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1801568","DOI":"10.1183\/13993003.01568-2018","article-title":"Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis","volume":"53","author":"Spencer","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: What we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)31462-9","article-title":"Oesophageal cancer","volume":"390","author":"Lagergren","year":"2017","journal-title":"Lancet"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2019.37.4_suppl.2","article-title":"Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study","volume":"37","author":"Kojima","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3322\/caac.21259","article-title":"Anal cancer: Current standards in care and recent changes in practice","volume":"65","author":"Shridhar","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMra1407550","article-title":"Testicular cancer--discoveries and updates","volume":"371","author":"Hanna","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0164-6","article-title":"The journey to CAR T cell therapy: The pediatric and young adult experience with relapsed or refractory B-ALL","volume":"9","author":"Hucks","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Hofmann, S., Schubert, M.L., Wang, L., He, B., Neuber, B., Dreger, P., Muller-Tidow, C., and Schmitt, M. (2019). Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). J. Clin. Med., 8.","DOI":"10.3390\/jcm8020200"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1001\/jama.2014.14553","article-title":"Chronic lymphocytic leukemia: A clinical review","volume":"312","author":"Nabhan","year":"2014","journal-title":"JAMA"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(03)13132-7","article-title":"Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: A systematic review","volume":"361","author":"Otto","year":"2003","journal-title":"Lancet"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","article-title":"Current thyroid cancer trends in the United States","volume":"140","author":"Davies","year":"2014","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa1114635","article-title":"Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy","volume":"366","author":"Schoen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/bjc.2016.290","article-title":"Impact of cervical screening on cervical cancer mortality: Estimation using stage-specific results from a nested case-control study","volume":"115","author":"Landy","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(10)60551-X","article-title":"Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: A multicentre randomised controlled trial","volume":"375","author":"Atkin","year":"2010","journal-title":"Lancet"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bmj.38516.649537.E0","article-title":"Skin biopsy rates and incidence of melanoma: Population based ecological study","volume":"331","author":"Welch","year":"2005","journal-title":"BMJ"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1600249","article-title":"Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of three decades of screening mammography on breast-cancer incidence","volume":"367","author":"Bleyer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41571-018-0116-x","article-title":"Active surveillance for prostate and thyroid cancers: Evolution in clinical paradigms and lessons learned","volume":"16","author":"Lowenstein","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","author":"Siu","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jnci\/djq099","article-title":"Overdiagnosis in cancer","volume":"102","author":"Welch","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMc1110293","article-title":"Reduced lung-cancer mortality with CT screening","volume":"365","author":"Bach","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/1055-9965.EPI-11-0476","article-title":"Mammography screening and risk of breast cancer death: A population-based case-control study","volume":"21","author":"Otto","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7326\/0003-4819-151-10-200911170-00009","article-title":"Screening for breast cancer: An update for the U.S. Preventive Services Task Force","volume":"151","author":"Nelson","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/jnci\/91.23.2020","article-title":"Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers","volume":"91","author":"Porter","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level <or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","article-title":"Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends","volume":"94","author":"Etzioni","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0022-5347(17)40078-4","article-title":"Clinical evidence for and implications of the multistep development of prostate cancer","volume":"143","author":"Carter","year":"1990","journal-title":"J. Urol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/oxfordjournals.aje.a009698","article-title":"Asymptomatic incidence and duration of prostate cancer","volume":"148","author":"Etzioni","year":"1998","journal-title":"Am. J. Epidemiol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(13)70216-X","article-title":"Assessment of volumetric growth rates of small colorectal polyps with CT colonography: A longitudinal study of natural history","volume":"14","author":"Pickhardt","year":"2013","journal-title":"Lancet. Oncol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1001\/jama.2016.6828","article-title":"Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force","volume":"315","author":"Knudsen","year":"2016","journal-title":"JAMA"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamainternmed.2016.0960","article-title":"Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial","volume":"176","author":"Bretthauer","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nmat4997","article-title":"Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma","volume":"16","author":"Xu","year":"2017","journal-title":"Nat. Mater."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41588-019-0423-x","article-title":"Quantitative evidence for early metastatic seeding in colorectal cancer","volume":"51","author":"Hu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1148\/radiol.11102120","article-title":"A dual-targeting anticancer approach: Soil and seed principle","volume":"260","author":"Li","year":"2011","journal-title":"Radiology"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00259-017-3744-y","article-title":"The potential of (223)Ra and (18)F-fluoride imaging to predict bone lesion response to treatment with (223)Ra-dichloride in castration-resistant prostate cancer","volume":"44","author":"Murray","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.18632\/oncotarget.12402","article-title":"Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity","volume":"8","author":"Werner","year":"2017","journal-title":"Oncotarget"},{"key":"ref_273","first-page":"553","article-title":"Molecular advances in pretargeting radioimunotherapy with bispecific antibodies","volume":"1","author":"Chang","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semradonc.2006.11.009","article-title":"Normal tissue tolerance dose metrics for radiation therapy of major organs","volume":"17","author":"Milano","year":"2007","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2009.02.089","article-title":"Radiation-Associated Kidney Injury","volume":"76","author":"Dawson","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2967\/jnumed.118.209841","article-title":"Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors","volume":"59","author":"Zhang","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semradonc.2005.04.005","article-title":"Partial volume tolerance of the liver to radiation","volume":"15","author":"Dawson","year":"2005","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-007-0457-7","article-title":"Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_280","first-page":"1323","article-title":"Human kidney as target for somatostatin: High affinity receptors in tubules and vasa recta","volume":"77","author":"Reubi","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_281","unstructured":"Abma, E. (2019, November 07). Ugent Is Looking For Dogs With Malignant Tumors. Available online: https:\/\/www.dierenartsenwereld.be\/nl\/nieuws-n2\/ugent-zoekt-honden-met-kwaadaardige-tumoren-i171\/."},{"key":"ref_282","unstructured":"(2019, November 07). OncoCiDia Phase 0 study (3M150468). Available online: https:\/\/www.kuleuven.be\/onderzoek\/portaal\/#\/projecten\/3M150468?hl=en&lang=en."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage","volume":"15","author":"Petrelli","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"55204","DOI":"10.18632\/oncotarget.19339","article-title":"Micro-HCCs in rats with liver cirrhosis: Paradoxical targeting effects with vascular disrupting agent CA4P","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease-latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/bjc.2017.210","article-title":"Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine","volume":"117","author":"Descotes","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41551-018-0343-6","article-title":"Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers","volume":"3","author":"Liu","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/ijc.25895","article-title":"Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ","volume":"129","author":"Sanger","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nature20609","article-title":"Mechanism of early dissemination and metastasis in Her2(+) mammary cancer","volume":"540","author":"Harper","year":"2016","journal-title":"Nature"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature20785","article-title":"Early dissemination seeds metastasis in breast cancer","volume":"540","author":"Hosseini","year":"2016","journal-title":"Nature"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/11\/1782\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:34:03Z","timestamp":1760189643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/11\/1782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":293,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["cancers11111782"],"URL":"https:\/\/doi.org\/10.3390\/cancers11111782","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]}}}